First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression Meeting Abstract
| Authors: | Gettinger, S. N.; Hellmann, M. D.; Shepherd, F. A.; Antonia, S. J.; Brahmer, J. R.; Chow, L. Q. M.; Goldman, J. W.; Juergens, R. A.; Borghaei, H.; Ready, N.; Gerber, D. E.; Nathan, F. E.; Shen, Y.; Harbison, C.; Rizvi, N. A. |
| Abstract Title: | First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901738 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.8025 |
| Notes: | Meeting Abstract: 8025 -- Source: Wos |
